To enhance your user experience on our website, this site uses cookies.
If you continue to browse, you accept the use of cookies on our site.
See our Privacy Policy
for more information.
Antisense oligonucleotides (ASOs) have evolved from niche experimental tools into a validated third pillar of drug discovery, standing alongside small molecules and biologics. By interacting directly with RNA, ASOs offer the unique ability to target the "undruggable genome"—proteins that lack enzymatic active sites or accessible pockets—thereby opening vast new frontiers in clinical application.